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Background: We studied the differences in immunoreactive trypsin (IRT) in neonatal screening for cystic fibrosis
(CF) associated individually with the age of the newborn, ethnicity and environmental temperature. In this study,
we determine the overall influence of environmental temperature at birth, gender, feeding, gestational age,
maternal age and ethnic origin on an abnormal IRT result.
Methods: Cross-sectional observational study. A sample was selected of newborns from Alicante (Spain) who
underwent neonatal CF screening in 2012–2013. Primary variable: abnormal IRT levels (≥65 ng/ml). Secondary
variables: gender, maternal origin, maternal age (years) (<20, 20–40, >40), gestational age (weeks) (<32, 32–37, >37),
type of feeding (natural, formula, mixed and special nutrition), >20 days from birth to blood collection, and average
temperature during the month of birth (in°C). Using a multivariate logistic regression model the adjusted odds
ratios (ORs) were estimated to analyze the association between atypical IRT levels and the study variables. The α
error was 5% and confidence intervals (CI) were calculated for the most relevant parameters.
Results: Of a total of 13,310 samples, 199 were abnormal (1.34%). Significant associated factors: feeding method
(natural→ OR = 1; mixed→ OR = 0.53, 95% CI: 0.31-0.89; formula→OR = 0.72, 95% CI: 0.48-1.07; special→OR =
21.88, 95% CI: 6.92-69.14; p < 0.001).
Conclusions: Newborns receiving special nutrition have a 20-fold higher risk for abnormal IRT levels, and screening
is advisable once normalized feeding is initiated. It is advisable to consider ethnic variability. Seasonality was
not important.
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Antecedentes: Se ha estudiado la diferencia de tripsina inmunorreactiva (TIR) en el cribado neonatal de fibrosis
quística (FQ) relacionados individualmente con edad del recién nacido, etnia y temperatura ambiente. En este
estudio nosotros determinamos la influencia global de temperatura ambiente al nacimiento, sexo, alimentación,
edad gestacional, edad de la madre y origen étnico sobre la TIR alterada.
Métodos: Estudio observacional transversal. Se seleccionó una muestra de recién nacidos de Alicante (España) a los
que se les realizó cribado neonatal de FQ en 2012–2013. Variable principal: niveles alterados de TIR (≥65 ng/ml).
Variables secundarias: sexo, origen de la madre, edad materna (años) (<20; 20–40; >40), semanas de gestación
(<32; 32–37; >37), tipo de lactancia (natural, artificial, mixta y nutrición especial), >20 días desde el nacimiento a la
extracción de sangre y temperatura media del mes de nacimiento (en°C). Con un modelo multivariante de
regresión logística se estimaron las odds ratio ajustadas (ORs) para analizar la relación entre la TIR atípica y las
variables del estudio. El error α fue del 5% y se calcularon intervalos de confianza (IC) para los parámetros más
relevantes.
Resultados: De un total de 13,310 muestras, 199 estuvieron alteradas (1.34%). Factores asociados significativos:
tipo alimentación (Materna→OR = 1; Mixta→OR = 0.53, IC 95%: 0.31-0.89; Fórmula→ OR = 0.72, IC 95%: 0.48-1.07;
Especial→ OR = 21.88, IC 95%: 6.92-69.14; p < 0.001).
Conclusiones: Los recién nacidos con nutrición especial tienen 20 veces más riesgo de TIR alterada, siendo
aconsejable cribarlos una vez inicien alimentación normalizada. Es aconsejable tener presente la variabilidad étnica.
La estacionalidad no fue importante.Background
Cystic fibrosis (CF) is one of the rare diseases for which
newborn screening is recommended [1] based on the de-
termination, in the first week of life, of immunoreactive
trypsin (IRT) in dried blood spots collected on filter
paper, because of its increased level in CF patients, likely
related to obstruction of the pancreatic ducts [2].
Studies have shown that children diagnosed through
screening have better nutritional and respiratory parame-
ters [3,4], better intellectual development [5,6], and in-
creased survival [7] than those diagnosed after presenting
clinical manifestations [8-11].
These benefits, coupled with successful experiences in
other countries and communities, have allowed imple-
mentation of newborn screening since that time. Newborn
screening in the Valencian Community began in 2012
by quantification of IRT, which is elevated in the blood
samples of newborns with cystic fibrosis due to pancre-
atic duct obstruction with trypsin reflux into the blood.
The critical point is the establishment of the cutoff in
the first sample. Each laboratory should establish its
own cutoffs, considering that the IRT concentration is
dependent on the age of the newborn and decreases
notably from 20–21 days of age. A protocol that has
proved effective is the three-stage strategy (IRT/DNA/
IRT) being used by several screening programs [12].
The main problem in the determination of IRT is a
higher than expected percentage of false positive tests
in some communities. The hypothesis is that the ref-
erence range for IRT may vary depending upon the
ethnicity of the newborn.The newborns of families from the north of Africa have
higher IRT values and most positive newborn screenings
in this population could be considered “false positives”
[13]. Higher IRT values have also been found to be associ-
ated with sick infants [14]. Despite these considerations,
no special strategy for premature infants and sick new-
borns is recommended. However, it may be useful to rec-
ord the ethnicity of the newborn to enable its association
with possible deviations in the analytical results. Cutoff
values at 48 hours of life can be set in different ways: an
absolute value, typically 60–65 ng/ml, although values up
to 90–105 ng/ml are acceptable, or a changing value based
on the results obtained over a period of time, which may
be a day or a month, accepting values higher than the
90th, 95th or 98th percentiles for that period as patho-
logical. All these findings have been summarized in an ex-
cellent review by Therrell Jr et al. [15].
Moreover, these factors have been individually ana-
lyzed for their impact on IRT values. As a new feature of
the findings of these authors, in this study we assessed
the conditions (room temperature, gender, gestational
age, age of the child at extraction, maternal age and eth-
nicity) that can alter the normal levels of IRT, after one
year of experience using a three-stage strategy protocol
(IRT/DNA/IRT) through multivariate analysis. Further-
more, we used an innovative approach to assess the in-
fluence of nutrition type on altered IRT values.
Methods
Study population
Newborns in the province of Alicante.
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Cross-sectional observational study. A sample of all new-
borns in the province of Alicante was selected to undergo
neonatal screening (IRT/DNA/IRT) for metabolic dis-
eases after informed consent was given by the parents
or guardians (over 99% of the newborns) from March
2012 to February 2013. The dried blood sample on
filter paper was required to meet the defined quality
criteria [16]. Any child not meeting these requirements
was excluded from the study. Additionally, all children
with CF were excluded since IRT distribution data could
be incorrect.Variables and measures
The primary variable was defined as altered levels of
IRT. This alteration was considered to be an IRT value
at or above 65 ng/ml. Quantification of IRT was per-
formed using the AutoDELFIA Neonatal IRT kit from
Perkin Elmer, initially establishing the cutoff value of IRT
at 65 ng/ml, as per the experiences of the majority of
Spanish laboratories performing this test according to the
Spanish Neonatal Screening Association (AECNE) [17].
Secondary variables were: child’s gender, country of origin
of the mother, maternal age (in years), gestational age (in
weeks), type of feeding (natural, formula, mixed and spe-
cial (nasogastric or intravenous), time from birth to blood
collection and average temperature of the month of birth
(in °C). The variables were grouped as follows: 1) Origin
of the mother: Spain, Africa, America, Rest of Europe and
Asia. This grouping was made based on the distribution of
the origin of mothers in recent years carried out by the
Department of Health of the Valencian Community [18];
2) Maternal age: <20, 20–40 and >40 years of age. 3) Ges-
tational age (in weeks): very preterm newborn <32, pre-
term from 32 to 37, and term ≥37. These intervals were
chosen based on the recommendations of the Standards
Committee of the Spanish Society of Neonatology [19];
and 4) day of extraction: <20 and ≥20. The cutoff was
chosen according to the screening protocol based on
quantification of IRT in a second sample after 20 days of
life [17].
Quantification of IRT was performed using AutoDELFIA
Neonatal IRT kit from Perkin Elmer and the average
temperature of the month of birth was obtained from
the Spanish Meteorological Agency (AEMET) [20]. The
remaining variables were obtained from the neonatal
screening report.Sample size
The final sample consisted of 13,310 children. With a
95% confidence level and a maximum expected propor-
tion (p = q =0.5), the estimated error of the proportion
of abnormal IRT was 0.85%.Statistical analysis
A descriptive analysis of the variables was performed. Ab-
solute and relative frequencies were used for qualitative
variables, while means, standard deviations and 95th and
99th percentiles were used for quantitative variables. Dif-
ferences were analyzed using nonparametric tests between
subgroups of gender, ethnicity, maternal age, gestational
age, type of feeding and days from birth to extraction of
the blood sample. A multivariate logistic regression model
was implemented to estimate the adjusted odds ratios
(ORs) with the aim of analyzing the relationship between
atypical IRT and the study variables. The ORs were ad-
justed by gender, origin of the mother, maternal age, gesta-
tional age group, feeding group, day of extraction group
and temperature. The goodness of fit of the model was
performed using the likelihood ratio test. In addition, we
worked with the predicted probabilities of atypical IRT
from the multivariate model to create graphs to help inter-
pret the results. All analyses were performed at the 5%
significance level and for each relevant parameter its asso-
ciated confidence interval (CI) was calculated. All analyses
were performed using IBM SPSS Statistics 19.
Missing data
The initial sample consisted of 14,877 newborns. How-
ever, those who did not have data for all the variables
were excluded from this sample, leaving the sample size
stated above.
Ethical issues
Neonatal screening studies were approved by the Ethics
Committee of the Valencian Community, requiring the
informed consent of the newborn’s parent or guardian,
in compliance with the current legislation in medical
ethics. Moreover, the data, which are data from routine
clinical practice in neonatal screening, were anonymized
and encrypted, satisfying the data protection law.
Results
The gestational age of the total sample was 39.0 (SD 1.9)
weeks, age at extraction was 5.4 (SD 3.3) days and mater-
nal age was 31.6 (SD 6.7) years. Average monthly tempera-
tures in Alicante during the period studied ranged from a
low in February of 12.1°C to a high of 27.7°C in August.
IRT values were not distributed normally according to the
Kolmogorov-Smirnov normality test (p <0.0001) with a
mean of 22.2 (SD 13.7) ng/ml, 95th percentile of 45.8 ng/
ml and 99th percentile of 69.4 ng/ml. Table 1 summarizes
the IRT data according to the groups established for the
different covariates in the total sample.
Table 2 summarizes the descriptive and analytical infor-
mation from the study sample (n = 13,310) according to
IRT cutoff values (65 ng/ml). Most of the mothers were
between 20 and 40 years of age (94.1%) and Spanish
Table 1 Immunoreactive trypsin values (in ng/ml) in newborn screening
Variable Mean (SD) 95% CI Percentile 95 Percentile 99
*Gender:
Male 21.5(13.7) 21.2-21.8 44.2 68.7
Female 22.8(13.5) 22.5-23.1 47.2 71.2
*Maternal origin:
Spain 22.2(13.7) 21.9-22.4 45.6 69.3
Africa 24.0(17.2) 23.0-25.1 54.0 94.8
South America 20.8(11.3) 20.1-21.5 41.7 63.6
Rest of Europe 22.3(12.6) 21.5-23.0 45.6 71.6
Asia 20.1(12.1) 18.9-21.4 46.2 69.3
**Maternal age (y):
<20 23.8(13.2) 22.5-25.1 52.0 73.3
20-40 22.1(13.7) 21.9-22.3 45.7 69.6
>40 22.9(14.2) 21.7-24.2 47.9 70.6
*Gestational age (w):
<32 25.0(16.7) 23.2-26.8 53.9 83.0
32-37 23.2(11.7) 22.5-24.0 46.6 65.9
>37 22.0(13.8) 21.8-22.3 45.4 69.5
*Feeding methods:
Natural 22.2(14.3) 21.9-22.4 46.1 71.5
Mixed 21.9(12.0) 21.4-22.4 44.0 62.8
Formula 22.2(12.4) 21.8-22.7 45.3 65.1
Special 53.3(52.9) 29.2-77.4 234.6 nd
*Extraction (d):
<20 22.2(13.9) 22.0-22.5 46.1 70.3
≥20 15.4(19.8) 10.3-20.6 48.0 nd
*Kruskal-Wallis test (p < 0.001); **Kruskal-Wallis test (p < 0.01).
nd: not determined.
2012–2013 data for a Spanish region.
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and were breastfeeding (65.0%).
The magnitude of atypical IRT was 1.5% (95% CI: 1.27-
1.68%). Associated factors: male (OR = 0.88, 95% CI: 0.66-
1.17, p = 0.385), maternal origin (Spain→OR= 1; Africa→
OR= 1.5, 95% CI: 0.95-2.37; South America→ 0.63, 95%
CI: 0.32-1.25; rest of Europe→ 0.88, 95% CI: 0.51-1.52;
Asia→ 1.21, 95% CI: 0.52-2.82; p = 0.219), maternal
age (<20→OR= 1.70, 95% CI: 0.83-3.49; 20-40→OR=
1; >40→OR= 1.06, 95% CI: 0.46-2.40; p = 0.353), gesta-
tional age (<32→OR= 1.45, 95% CI: 0.49-4.25; 32-37→
OR= 0.59, 95% CI: 0.33-1.05; >37→OR= 1; p = 0.137),
feeding method (natural→OR = 1; mixed→OR = 0.53,
95% CI: 0.31-0.89; formula→OR = 0.72, 95% CI: 0.48-
1.07; special→OR = 21.88, 95% CI: 6.92-69.14; p <
0.001), >20 days from extraction (OR = 1.51, 95% CI:
0.21-11.13, p = 0.684), and temperature (OR = 0.98,
95% CI: 0.95-1.00, p = 0.064).On a Cartesian graph (Figure 1) feeding groups were
plotted on the X-axis and predicted probabilities of atyp-
ical IRT on the Y-axis. This graph shows that the new-
borns who received special nutrition were more likely to
have atypical IRT.
Discussion
When the differences in the IRT concentration in the
total sample were studied according to type of feeding,
IRT concentrations did not vary significantly between
the three feeding groups (breastfeeding, formula and
mixed). However, the elevated IRT levels in neonates re-
ceiving special feeding was striking, showing a significant
difference. The mean IRT rose to more than double that
of the other newborns, with many more of these new-
borns having IRT values above the cutoff. This was con-
firmed in the multivariate analysis, which showed that
the probabilities of newborns receiving special nutrition
Table 2 Analysis of atypical immunoreactive trypsin (≥65 ng/ml) in newborns in a Spanish region
Variable Total 13310
n(%)/x ± s
AIT 196 (1.5%)
n(%)/x ± s
Not AIT 13114
(98.5%) n(%)/x ± s
Adj. OR 95% CI (Adj. OR) p-value
Gender male 6861(51.5) 95(48.5) 6766(51.6) 0.88 0.66-1.17 0.385
Maternal origin:
Spain 9994(75.1) 144(73.5) 9850(75.1) 1 1 0.219
Africa 953(7.2) 22(11.2) 931(7.1) 1.50 0.95-2.37
South America 967(7.3) 9(4.6) 958(7.3) 0.63 0.32-1.25
Rest of Europe 1061(8.0) 15(7.7) 1046(8.0) 0.88 0.51-1.52
Asia 335(2.5) 6(3.1) 329(2.5) 1.21 0.52-2.82
Maternal age (years):
<20 358(2.7) 8(4.1) 350(2.7) 1.70 0.83-3.49 0.353
20-40 12531(94.1) 182(92.9) 12349(94.2) 1 1
>40 421(3.2) 6(3.1) 415(3.2) 1.06 0.46-2.40
Gestational age (weeks):
<32 146(1.1) 6(3.1) 140(1.1) 1.45 0.49-4.25 0.137
32-37 1568(11.8) 13(6.6) 1555(11.9) 0.59 0.33-1.05
>37 11596(87.1) 177(90.3) 11419(87.1) 1 1
Feeding method:
Natural 8698(65.3) 144(73.5) 8554(65.2) 1 1 <0.001
Mixed 1902(14.3) 16(8.2) 1886(14.4) 0.53 0.31-0.89
Formula 2689(20.2) 30(15.3) 2659(20.3) 0.72 0.48-1.07
Special 21(0.2) 6(3.1) 15(0.1) 21.88 6.92-69.14
Days from extraction >20 47(0.4) 1(0.5) 46(0.4) 1.51 0.21-11.13 0.684
Temperature (°C) 18.7 ± 5.6 18.0 ± 5.2 18.8 ± 5.6 0.98 0.95-1.00 0.064
Abbreviations: AIT atypical immunoreactive trypsin, Adj. OR adjusted odds ratio, CI confidence interval.
Goodness-of-fit of the model: Χ2 = 53.19, p < 0.001.
ORs were adjusted for: gender, maternal origin, maternal age, gestational age, feeding method, days from extraction and temperature.
2012–2013 data.
Figure 1 Predicted probability of atypical immunoreactive
trypsin between feeding methods in newborns in a Spanish
region. 2012–2013 data.
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those who were fed. This is undoubtedly associated with
the fact that these children were subjected to special nu-
trition, due to their inherent disease, causing the in-
crease in IRT. Although IRT is elevated in individuals
with CF, an increase in IRT has also been seen in normal
individuals with an immature ductal system, carriers of
CF (66%), and in neonates with other diseases such as
trisomy of chromosome 13, 18 and 21 [21], congenital
infections (cytomegalovirus and other subclinical infec-
tions), renal failure, inadequate pancreatic perfusion and
intestinal atresia. Higher IRT values are also associated
with perinatal asphyxia [22] and sick infants [14]. On
the other hand it has been reported that prenatal stress
may be responsible for up to 25% of positive cases [22].
When IRT concentrations were examined by maternal
ethnicity, clearly higher values were observed in new-
borns of African origin, with significant differences, a
finding consistent with the literature [23]. In addition,
slightly lower IRT values were found in infants of Asian
and American mothers. On comparing newborns of
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variate analysis, there was an almost significant differ-
ence and a greater probability (OR 1.6) that the neonate
of an African mother was more likely to have IRT levels
above the reference value. Ethnic influence on IRT level
has been studied previously [24], showing an overrepre-
sentation of African Americans in screen-positive new-
born infants (10% of the general population, rising to
28% in the positive population) despite the lower inci-
dence of CF in this population. Note that in the present
study maternal origin was divided into: Spain, rest of
Europe, Africa, America and Asia; although Africa here
corresponded primarily to countries in north Africa
(mainly Morocco). Thus, newborns from north African
families have higher IRT values and most of the positive
newborn screens in this population could be considered
“false positives” [13]. It should be noted that CF is the
most common genetic disorder among Caucasian chil-
dren. The incidence is variable: it is much less common
in Asian and African populations than in European
and North American populations, with variations within
each country. The prevalence varies between a max-
imum of 1/2000 in Ireland and a minimum of 1/500,000
in Japan [23,24].
With respect to the other factors analyzed in this
study, most behaved similarly to findings previously de-
scribed by other authors [15,23,24], with the exception
of temperature. This is possibly due to the variability be-
tween minimum and maximum temperatures through-
out the year being much lower than in the regions in
which this association has been observed [25]. Finally,
there was no association with maternal age. This must
be verified by future studies.
This work shows the need to establish cutoffs in IRT
values adjusted to the ethnic and prematurity character-
istics of the study population, as well as the need to
postpone screening in those infants with conditions that
require special feeding. This has the potential to reduce
the number of inconclusive results, in which a second
marker must be measured, either through DNA muta-
tion analysis or taking a second sample for IRT retesting,
thereby resulting in lower economic and emotional costs
to the parents caused by unnecessary confirmations.
Strengths and limitations
The main strength of this study is its innovative ap-
proach to analyzing nutrition type when altered IRT
values are present. Ethnicity is also evaluated in a man-
ner different from that used by other authors. Further-
more, these factors were analyzed taking into account
the ratio of all the altered IRT values, that is, through a
mathematical multivariate model. Finally, the random
error was less than 1%. As limitations, the IRT values an-
alyzed are only useful for the population studied. Eachneonatal cystic fibrosis screening center must define its
own cutoff values and to do this the same methodology
used in this work could be followed. Moreover, to
minimize information bias, great care was taken in the
collection of all variables. In addition, to avoid selection
bias, all children who underwent neonatal screening
were included. Finally, although the statistical signifi-
cance of the special type of nutrition was quite high, a
wide confidence interval was obtained, therefore, in order
to quantify OR more precisely, future studies using a lar-
ger sample size are needed.
Conclusions
In conclusion, newborns receiving special nutrition have
much higher IRT values, with a 20-times greater likelihood
of being above the set reference value, no doubt due to the
underlying disease state. Thus, CF screening is advisable in
sick infants with a special diet once breastfeeding, formula
or mixed feeding is initiated. Newborns of African ethni-
city, specifically children born to north African mothers,
have higher IRT levels than those of other ethnic groups.
An important factor to bear in mind is the increased ethnic
variability resulting from increased migration.
The main learning point from this study is that we
have to adopt new IRT cutoff points for children of cer-
tain ethnic backgrounds and for those who follow a spe-
cial diet. However, we must be cautious, as these results
must be verified by other authors in studies incorporat-
ing a large number of newborns.
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